MONTGOMERY, Ala.--(BUSINESS WIRE)--Aug. 17, 2006--ProEthic Pharmaceuticals, Inc., a privately funded specialty pharmaceutical company that acquires, develops and markets niche prescription products, announced today positive results from two Phase I trials for PRO-571, the company’s product candidate for the treatment of acute pain.
